Clinical trials: Infections, Respiratory
Respiratory Syncytial Virus Infections
Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women
The purpose of this study is to assess the safety and reactogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged 18 to 45 years.
- Trial name
- NCT02753413
- Testing
- RSV vaccine GSK3003891A, Boostrix
- Where
- Belgium
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac）manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04894227
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell）
- Where
- China
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Influenza
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT06574503
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345
The purpose of this study is to assess the safety and immunogenicity of GSK Biologicals' investigational vaccine GSK2321138A in children who previously participated in study 115345 (FLU D-QIV-004 PRI) (NCT01439360).
- Trial name
- NCT01702454
- Testing
- Fluarix Quadrivalent
- Where
- 33 sites in Czechia, Poland and 2 more
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Infections, Urinary Tract Infections
Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under…
- Trial name
- PIP-SBT (NCT01897831)
- Testing
- xin te mie
- Volunteers
- 2,000 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Influenza
Ellume.Lab Flu A+B Test and iTreat Flu A+B Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction.
The primary purpose of this study is to validate the sensitivity and specificity of the iTreat Flu A+B Test and the ellume.lab Flu A+B Test in detecting influenza A and influenza B as compared to viral culture.
- Trial name
- NCT03248960
- Testing
- iTreat Flu A+B Test, ellume.lab Flu A+B Test, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
- Where
- 8 sites in Australia
- Volunteers
- 381 people
- Sponsor
- Ellume Pty Ltd
Streptococcus Pneumonia, Vaccine Preventable Disease
Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
The current study provides data necessary to evaluate the safety and immunogenicity of Serum Institute of India's PNEUMOSIL® [Pneumococcal Polysaccharide Conjugate Vaccine Adsorbed (10-Valent)] in Healthy Vietnamese Infants and…
- Trial name
- PNEUMOSIL (NCT05140720)
- Testing
- PNEUMOSIL®
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vabiotech
Healthy
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway.
- Trial name
- NCT04731324
- Testing
- ZYIL1 capsule
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Gastrointestinal Diseases
DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect
To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in antibiotic-treated children with complicated…
- Trial name
- NCT00424905
- Testing
- Bacillus clausii
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Sanofi
Diphtheria, Tetanus
A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
This is a randomized, blinded, controlled phase II and III clinical trial evaluating the immunogenicity and safety of adsorbed cell-free DPT vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT06708286
- Testing
- Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp
- Where
- China
- Volunteers
- 1,820 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Diphtheria, Tetanus
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months
As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety of sanofi pasteur's DTacP-IPV// PRP~T combined vaccine (PENTAXIM™) as a three-dose primary vaccination at 2, 3, and 4…
- Conditions
- Diphtheria, Tetanus, Haemophilus Influenzae Type b, Pertussis
- Trial name
- NCT00453570
- Testing
- Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib, Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed
- Where
- China
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi
Sinusitis
Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis
This post-market study aims to compare health outcomes for Chronic Rhinosinusitis (CRS) patients treated with balloon sinus dilation (BSD) versus continued medical management.
- Trial name
- MERLOT (NCT01685229)
- Testing
- Balloon sinus dilation, Medical Management
- Where
- 20 sites in United States
- Volunteers
- 198 people
- Sponsor
- Integra LifeSciences Corporation
COVID-19 Pneumonia
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome.
- Trial name
- NCT04449588
- Testing
- BDB-001 Injection, Conventional treatment
- Where
- 12 sites in Bangladesh, China and 3 more
- Volunteers
- 369 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
- Trial name
- NCT00985088
- Testing
- GSK2340274A, GSK2340273A
- Where
- 14 sites in United States, Canada
- Volunteers
- 1,343 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Cold
Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants
This will be a single-center, randomized, parallel-group, placebo-controlled study to assess the local nasal tolerability and safety of multiple administrations of topically (intranasally) administered 1146A delivered by a nasal…
- Trial name
- NCT02832362
- Testing
- Carbomer 980
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with…
- Trial name
- NCT05238454
- Testing
- SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2 Infection
A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
To evaluate the immunogenicity and safety of a COVID-19 mRNA vaccine (ZSVG-02-O) in a healthy population aged 18 years and older.
- Trial name
- NCT06113731
- Testing
- COVID-19 mRNA Vaccine (ZSVG-02-O), COVID-19 Vaccine (Vero Cell) ,Inactivated
- Where
- 2 sites in China
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic. Study objectives: To describe the safety profiles in the periods following each vaccination in subjects receiving…
- Conditions
- Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections
- Trial name
- NCT00884182
- Testing
- A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
- Where
- 13 sites in Finland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.